Who was studied, and how
Six numbers in the abstract
Where each one falls
Where it lands on the map
197,716people with cardiovascular disease, in this paper
Already taking statin use, or nottheir own situation, not assigned
on statin use
statin nonuse
No clear link with fatal/nonfatal myocardial infarction or stroke+0%
Statin use went with fewer deaths−4%
No clear link with composite risk of all-cause mortality, nonfatal myocardial infarction, or stroke thereafter−2%
correlation, not a testthe abstract, start to end
… or stroke overall (hazard ratio [HR] 1.00, 95% CI 0.97-1.02), or in subgroups (age< 50 years [HR = 1.05, 95% CI 0.95-1.17]; waitlisted for kidney transplant [HR 0.99, 95% CI 0.97-1.02]).
… with lower all-cause mortality (HR 0.96, 95% CI 0.94-0.98; E value = 1.21) and, similarly, a modest lower composite risk of all-cause mortality, nonfatal myocardial infarction, or stroke over the first 2 years (HR 0.90, 95% CI 0.88-0.91) but …
← favours treatmentfavours comparator →
could be chanceFatal/nonfatal myocardial infarction or strokestatin use vs statin nonuse
HR 1.000.97–1.02
Fatal/nonfatal myocardial infarction or strokestatin use vs statin nonuse, in age< 50 years
HR 1.050.95–1.17
Fatal/nonfatal myocardial infarction or strokestatin use vs statin nonuse, in waitlisted for kidney transplant
HR 0.990.97–1.02
All-cause mortalitystatin use vs statin nonuse
HR 0.960.94–0.98
Composite risk of all-cause mortality, nonfatal myocardial infarction, or stroke thereafterstatin use vs statin nonuse
HR 0.980.96–1.01
Composite risk of all-cause mortality, nonfatal myocardial infarction, or stroke over the first 2 yearsstatin use vs statin nonuse
HR 0.900.88–0.91
StatinsCardiovascular eventsAll-cause mortality
1 / 4